Deoxygedunin

With intraperitoneal injection to mice, deoxygedunin crosses the blood-brain-barrier into the central nervous system and possesses a long duration of action, with onset of action at 2 hours post-administration and peaking between 4–8 hours.^[1] Relative to 7,8-DHF, deoxygedunin has weaker binding affinity for TrkB (K_d = 1.4 μM).^[1][2] However, it is more potent than 7,8-DHF in vivo with intraperitoneal injection in multiple assays.^[1] Deoxygedunin has also been found to be orally and topically active.^[1][4] The compound, in contrast to 7,8-DHF, has poor water solubility,^[1] and hence its bioavailability, especially oral, may be suboptimal.^[6] The researchers who discovered deoxygedunin expressed that they were attempting to find analogues with improved water solubility that retained the biological activity of deoxygedunin, but, as of 2016, there appear to have been no subsequent reports on this effort since the original paper (2010) was published.^[1] They also stated in the paper that 7,8-DHF has a simpler chemical structure and that the flavonoids were easier to modify for improved biological effects than the gedunins.^[1]

Similarly to gedunin, a closely structurally related compound also found in Azadirachta indica, deoxygedunin has additionally been found to activate HSF1 and induce Hsp70, and was observed to possess neuroprotective effects in a model of Huntington's disease.^[7]

• Tropomyosin receptor kinase B § Agonists